Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study

BACKGROUND: SOX (oxaliplatin and S1, every 3 weeks) is one of the most common first-line chemotherapy for advanced or metastatic G/GEJ (gastric or gastroesophageal junction) cancer in Asia, but it has noticeable hematological and neurological toxicity. In China, the majority of gastric cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhichao, Zhou, Aiping, Sun, Yongkun, Zhang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908595/
https://www.ncbi.nlm.nih.gov/pubmed/35264150
http://dx.doi.org/10.1186/s12885-022-09332-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908595/
https://www.ncbi.nlm.nih.gov/pubmed/35264150
http://dx.doi.org/10.1186/s12885-022-09332-7

Ejemplares similares